Helix Biopharma Corp Stock Target Price
| HBPCF Stock | USD 1.73 1.13 188.33% |
Fundamental analysis of Helix BioPharma allows traders to better anticipate movements in Helix BioPharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
Helix |
Helix Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Helix BioPharma's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Helix BioPharma could also be used in its relative valuation, which is a method of valuing Helix BioPharma by comparing valuation metrics of similar companies.Helix BioPharma is currently under evaluation in target price category among its peers.
Helix Fundamentals
| Return On Equity | -12.06 | |||
| Return On Asset | -1.04 | |||
| Current Valuation | 30.65 M | |||
| Shares Outstanding | 200.02 M | |||
| Shares Owned By Insiders | 18.35 % | |||
| Shares Owned By Institutions | 13.10 % | |||
| Number Of Shares Shorted | 2.27 K | |||
| Price To Earning | (6.52) X | |||
| Price To Book | 134.72 X | |||
| EBITDA | (6.53 M) | |||
| Net Income | (6.56 M) | |||
| Cash And Equivalents | 1.88 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 2.88 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 0.69 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (6.51 M) | |||
| Short Ratio | 3.83 X | |||
| Earnings Per Share | (0.04) X | |||
| Beta | -0.56 | |||
| Market Capitalization | 29.76 M | |||
| Total Asset | 3.73 M | |||
| Working Capital | 20.41 M | |||
| Current Asset | 22.72 M | |||
| Current Liabilities | 2.32 M | |||
| Z Score | 8.7 | |||
| Net Asset | 3.73 M |
About Helix BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Helix BioPharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Helix BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Helix BioPharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Other Information on Investing in Helix Pink Sheet
Helix BioPharma financial ratios help investors to determine whether Helix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.